Three-year mortality in relation to early hospitalization and number of outpatient clinic visits in people with newly diagnosed bipolar disorder

General Hospital Psychiatry

Volumn 43, Issue , 2016, Pages 32-37

  Pan, Yi Ju ^a,b   Yeh, Ling Ling ^c   Chen, Yu Chun ^b   Chan, Hung Yu ^d,e  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d Taoyuan Psychiatric Center   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bipolar disorder; Hospitalization; Mortality; Substance use disorder; Treatment adherence

Indexed keywords

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; NEOPLASM; OUTPATIENT CARE; SURVIVAL ANALYSIS; SYMPTOM; AGED; AMBULATORY CARE; EPIDEMIOLOGY; MIDDLE AGED; OUTPATIENT DEPARTMENT; STATISTICS AND NUMERICAL DATA; TAIWAN; YOUNG ADULT;

ADULT; AGED; AMBULATORY CARE; AMBULATORY CARE FACILITIES; BIPOLAR DISORDER; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SUBSTANCE-RELATED DISORDERS; TAIWAN; YOUNG ADULT;

EID: 84988486100     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2016.08.007     Document Type: Article

References (41)

1. [1] Hoang, U, Stewart, R, Goldacre, MJ, Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ, 343, 2011, d5422.
2. [2] Kessing, LV, Vradi, E, Andersen, PK, Life expectancy in bipolar disorder. Bipolar Disord 17 (2015), 543–548.
3. [3] Carlborg, A, Ferntoft, L, Thuresson, M, Bodegard, J, Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study. Bipolar Disord 17 (2015), 76–85.
4. [4] Goldstein, BI, Schaffer, A, Wang, S, Blanco, C, Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. J Clin Psychiatry 76 (2015), 163–169.
5. [5] Weiner, M, Warren, L, Fiedorowicz, JG, Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry 23 (2011), 40–47.
6. [6] Andrade, C, Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins. Bipolar Disord 15 (2013), 813–823.
7. [7] Laursen, TM, Nordentoft, M, Heart disease treatment and mortality in schizophrenia and bipolar disorder — changes in the Danish population between 1994 and 2006. J Psychiatr Res 45 (2011), 29–35.
8. [8] Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P, Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58 (2001), 844–850.
9. [9] Sylvia, LG, Shelton, RC, Kemp, DE, Bernstein, EE, Friedman, ES, Brody, BD, et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE. Bipolar Disord 17 (2015), 212–223.
10. [10] Fiedorowicz, JG, Solomon, DA, Endicott, J, Leon, AC, Li, C, Rice, JP, et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 71 (2009), 598–606.
11. [11] Murray, DP, Weiner, M, Prabhakar, M, Fiedorowicz, JG, Mania and mortality: why the excess cardiovascular risk in bipolar disorder?. Curr Psychiatry Rep 11 (2009), 475–480.
12. [12] Costa Lda, S, Alencar, AP, Nascimento Neto, PJ, dos Santos Mdo, S, da Silva, CG, Pinheiro Sde, F, et al. Risk factors for suicide in bipolar disorder: a systematic review. J Affect Disord 170 (2015), 237–254.
13. [13] Moeller, FG, Barratt, ES, Dougherty, DM, Schmitz, JM, Swann, AC, Psychiatric aspects of impulsivity. Am J Psychiatry 158 (2001), 1783–1793.
14. [14] de Almeida, KM, Moreira, CL, Lafer, B, Metabolic syndrome and bipolar disorder: what should psychiatrists know?. CNS Neurosci Ther 18 (2012), 160–166.
15. [15] Taylor, V, MacQueen, G, Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 67 (2006), 1034–1041.
16. [16] Perlick, DA, Rosenheck, RA, Kaczynski, R, Kozma, L, Medication nonadherence in bipolar disorder: a patient-centered review of research findings. Clin Approach Bipolar Disord 3 (2004), 56–64.
17. [17] Martinez-Aran, A, Scott, J, Colom, F, Torrent, C, Tabares-Seisdedos, R, Daban, C, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 70 (2009), 1017–1023.
18. [18] Hong, J, Reed, C, Novick, D, Haro, JM, Aguado, J, Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 190 (2011), 110–114.
19. [19] National Health Insurance Administration, Enrollment and underwriting. Available from: http://www.nhi.gov.tw/Resource/webdata/Attach_14277_2_97%E6%89%BF%E4%BF%9D-en.pdf [Last accessed Oct 1, 2015].
20. [20] World Economic Outlook (WEO) data. Implied PPP (purchasing power parity) conversion rate. Available from: http://www.econstats.com/weo/V013.htm [Last accessed Oct 1, 2015].
21. [21] Liu, CY, Hung, YT, Chuang, YL, Chen, YJ, Weng, WS, Liu, JS, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 4 (2006), 1–22.
22. [22] National Health Insurance Administration, Available from: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=19&menu_id=705&webdata_id=3466 [Last accessed Oct 2, 2015].
23. [23] CY, W, Chen, YJ, Ho, HJ, Hsu, YC, Kuox, YC, Wu, MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308 (2012), 1906–1914.
24. [24] Pan, YJ, Yeh, LL, Chen, YC, Kuo, KH, Chang, CK, Hospital treatment, mortality and healthcare costs in relation to socioeconomic status among people with bipolar affective disorder. Br J Psychiatry Open 2 (2016), 10–17.
25. [25] Altamura, AC, Buoli, M, Caldiroli, A, Caron, L, Cumerlato Melter, C, Dobrea, C, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord 182 (2015), 70–75.
26. [26] Gonzalez-Pinto, A, Mosquera, F, Alonso, M, López, P, Ramírez, F, Vieta, E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8 (2006), 618–624.
27. [27] Simpson, SH, Eurich, DT, Majumdar, SR, Padwal, RS, Tsuyuki, RT, Varney, J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ, 333, 2006, 15.
28. [28] D'Souza, R, Piskulic, D, Sundram, S, A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial. J Affect Disord 120 (2010), 272–276.
29. [29] Batista, TA, Baes, CVW, Juruena, MF, Efficacy of psychoeducation in bipolar patients: systematic review of randomized trials. Psychol Neurosci 4 (2011), 409–416.
30. [30] American Diabetes, A, American Psychiatric, A, American Association of Clinical E, North American Association for the Study of O, Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004), 596–601.
31. [31] Morrato, EH, Druss, B, Hartung, DM, Valuck, RJ, Allen, R, Campagna, E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 67 (2010), 17–24.
32. [32] Newcomer, JW, Nasrallah, HA, Loebel, AD, The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24 (2004), S1–S6.
33. [33] Buckley, PF, Miller, DD, Singer, B, Arena, J, Stirewalt, EM, Clinicians– recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79 (2005), 281–288.
34. [34] Gierisch, JM, Nieuwsma, JA, Bradford, DW, Wilder, CM, Mann-Wrobel, MC, McBroom, AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry 75 (2014), e424–e440.
35. [35] Parameswaran, SG, Chang, C, Swenson, AK, Shumway, M, Olfson, M, Mangurian, CV, Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists. Schizophr Res 143 (2013), 395–396.
36. [36] Phillips, LS, Branch, WT, Cook, CB, Doyle, JP, El-Kebbi, IM, Gallina, DL, et al. Clinical inertia. Ann Intern Med 135 (2001), 825–834.
37. [37] Lagerberg, TV, Andreassen, OA, Ringen, PA, Berg, AO, Larsson, S, Agartz, I, et al. Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study. BMC Psychiatry, 10, 2010, 9.
38. [38] Hoblyn, JC, Balt, SL, Woodard, SA, Brooks, JO III, Substance use disorders as risk factors for psychiatric hospitalization in bipolar disorder. Psychiatr Serv 60 (2009), 50–55.
39. [39] Cerullo, MA, Strakowski, SM, The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy, 2, 2007, 29.
40. [40] Swann, AC, The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci 1187 (2010), 276–293.
41. [41] Powers, RL, Russo, M, Mahon, K, Brand, J, Braga, RJ, Malhotra, AK, et al. Impulsivity in bipolar disorder: relationships with neurocognitive dysfunction and substance use history. Bipolar Disord 15 (2013), 876–884.